Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

about

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q41148890

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

@en

type

Item

label

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

@en

prefLabel

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

@en

P1476

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.

@en

P2093

Chi Pan

http://www.w3.org/2001/XMLSchema#string

Jianjin Huang

http://www.w3.org/2001/XMLSchema#string

Ling Ding

http://www.w3.org/2001/XMLSchema#string

Shanshan Weng

http://www.w3.org/2001/XMLSchema#string

Suzhan Zhang

http://www.w3.org/2001/XMLSchema#string

Yin Duan

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.

ZD1839 ('Iressa') as an anticancer agent.

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

STAT-mediated EGFR signaling in cancer.

The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines.

Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.

Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity.

P304

320-326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/WO.2016.61853

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27688730

http://www.w3.org/2001/XMLSchema#string

P932

5032161

http://www.w3.org/2001/XMLSchema#string